{
  "attach_pages": "9",
  "attach_size": "735",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201801101076125456_1.pdf?1515617672000.pdf",
  "company_code": "80000038",
  "eitime": "2018-01-10 20:54:58",
  "extend": {},
  "info_code": "AP201801101076125456",
  "language": "0",
  "notice_date": "2018-01-10 00:00:00",
  "notice_title": "授权BTK抑制剂，海外创新药战略显成效",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "BB",
  "researcher": "肖汉山",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "恒瑞医药",
      "short_name_ch": "恒瑞医药",
      "short_name_cht": "恒瑞醫藥",
      "short_name_en": "HENGRUI PHARMA",
      "stock": "600276"
    }
  ],
  "short_name": "恒瑞医药",
  "source_sample_name": "民生证券",
  "star": "3"
}